Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Orion Corporation, Orion Pharma |
---|---|
Information provided by: | Orion Corporation, Orion Pharma |
ClinicalTrials.gov Identifier: | NCT00219388 |
The purpose of this study is to compare the effects of levosimendan with dobutamine on heart function in patients suffering of severe chronic heart failure.
Condition | Intervention | Phase |
---|---|---|
Heart Failure |
Drug: Levosimendan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy and Safety of Short-Term Intravenous Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients Treated With Beta-Receptor Blocking Agents. |
Estimated Enrollment: | 60 |
Study Start Date: | November 2002 |
Estimated Study Completion Date: | April 2005 |
Patients with decompensate heart failure (NYHA III-IV) and in need of intravenous inotrop support and who fulfil all inclusion and no exclusion criteria will be randomised into the study in proportion 1:1. Although stratification will be done so patients treated with beta-receptor blocker carvedilol will be divided the same between the study groups. All patients will receive infusions in parallell, one of the groups will receive active product (levosimendan or dobutamine) and the other will receive placebo (double-dummy technique). Catheterisation for measurement of hemodynamic parameters will be performed according to routine methods at the clinic. The measurements of the hemodynamic variables will start 30 minutes before start of study drug infusion and will be finished 48 hours after start of infusion. The most important variables during the measurements is Cardiac Index (CI)and Pulmonary Capillary Wedge Pressure (PCWP). Parallel registration will be done on ECG, blood pressure, blood frequency, central venous pressure, and lung artery pressure. Heart failure and other clinical symptoms will be registered continuously during 48 hours. Blood samples will be taken intermittent to record the blood values. Cogent rules for decreasing/increasing of the dose can be found in the study protocol, likewise rules for interruption or stoop for infusion.
Registration of side-effects will be done continuously. The recommendation for treatment for known side effects could be found in the protocol (section 5.3.4) and the protocol should be available during the study procedure. One month after the study the patients will be followed up with a very careful examination and also of the amount of visits and reason for visits to hospital during the past 30-35 days.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
Main Exclusion Criteria:
Sweden | |
Cardiology Department, Sahlgrenska University Hospital | |
Gothenburg, Sweden, 413 45 |
Principal Investigator: | Claes-Håkan Bergh, Assoc Prof | Institution of Cardiology, Sahlgrenska University Hospital, Sweden |
Study ID Numbers: | 3001075, Sponsor: Orion Pharma |
Study First Received: | September 14, 2005 |
Last Updated: | September 21, 2005 |
ClinicalTrials.gov Identifier: | NCT00219388 History of Changes |
Health Authority: | Sweden: Swedish National Council on Medical Ethics |
Safety Efficacy Levosimendan Dobutamine |
Intravenous Invasive hemodynamics Decompensated Heart Failure |
Vasodilator Agents Heart Failure Phosphodiesterase Inhibitors Heart Diseases |
Cardiovascular Agents Anti-Arrhythmia Agents Dobutamine Simendan |
Heart Failure Vasodilator Agents Heart Diseases Molecular Mechanisms of Pharmacological Action Cardiotonic Agents Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents |
Protective Agents Pharmacologic Actions Simendan Phosphodiesterase Inhibitors Therapeutic Uses Cardiovascular Diseases Anti-Arrhythmia Agents |